
Cosmos Health revenue hits $53.6 million, up 17.6%
Key points
- Cosmos Health reported nine-month 2026 revenue of $53.6 million, up 17.6% year over year, although its net loss widened to $14.15 million.
- The company reduced total debt by 33.8% to $12.83 million and increased stockholders' equity by 21.2% to $22.33 million, while fully settling its $8 million ATW convertible note.
- Cana Laboratories expanded its contract manufacturing pipeline by 31% to more than 32.7 million units, as Cosmos Health continued efforts to strengthen its manufacturing operations and financial position.
Cosmos Health (NASDAQ:COSM) reported nine-month 2026 revenue of $53.59 million, up 17.6% from $45.57 million a year earlier, while its net loss widened to $14.15 million.
Third-quarter revenue declined to $16.68 million from $17.11 million, while the quarterly net loss narrowed to $5.25 million from $5.35 million and gross margin improved to 12.6% from 7.96% in the second quarter.
The nine-month loss included higher noncash interest and convertible-note valuation expenses, while total debt declined 33.8% to $12.83 million and stockholders' equity increased 21.2% to $22.33 million.
Following the announcement, Cosmos Health shares were unchanged at $2.85 in early trading on November 18, matching the previous session's closing price.
Meanwhile, Cana Laboratories increased its contract manufacturing pipeline by 31% since June to more than 32.7 million units across 11 therapeutic categories, representing over $20 million in estimated revenue and more than $18 million in implied gross profit.
Cosmos Health also fully settled its $8 million ATW convertible note approximately one year before maturity, launched a US subscription business that reached more than 12,500 active subscriptions by October 31, and completed a 1-for-20 reverse stock split effective November 13.
Frequently asked questions
More from United States
Summit launches Phase III lung cancer trial for ivonescimab
DataMeds AI issues 630,000 shares in cancer partnership
CoinShares net income improves 27% to $39.6 million
newcleo revenue skyrockets 26% to €10 million in Q3
Kandi reports 38.5% increase in quarterly revenue
BellRing sales advances 6.8% to $692 million



